Want to see IT:PHIL full AI Analyst Report?
Top Page
Philogen SpA
(PHIL)
Select Model
Select Model
Rating:86Outperform
Price Target:
€28.00
▲(20.95% Upside)
Action:Reiterated
Date:08/06/26
Philogen's exceptionally high stock score is primarily driven by an extraordinary fundamental turnaround, characterized by explosive margin expansion, immense free cash flow generation, and a pristine balance sheet. Furthermore, the stock offers a deeply discounted valuation with a 4.19 P/E ratio and a solid dividend yield. While short-term technical momentum is currently sluggish, the company's elite financial health provides a robust foundation.
Positive Factors
Revenue & Profitability Surge
The sharp increase in revenue and net income indicates the company reached meaningful commercial or milestone-driven scale, improving internal funding capacity. Sustained higher revenue and margins can finance R&D, reduce reliance on external funding, and support strategic partnerships over the next several quarters.
Negative Factors
Revenue Volatility / Lumpiness
A revenue profile driven by irregular milestones or one-off events undermines predictability of future cash flows. For a clinical-stage biopharma, milestone-dependent income can reverse quickly if trials or partner payments shift, complicating multi-quarter planning and valuation.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & Profitability Surge
The sharp increase in revenue and net income indicates the company reached meaningful commercial or milestone-driven scale, improving internal funding capacity. Sustained higher revenue and margins can finance R&D, reduce reliance on external funding, and support strategic partnerships over the next several quarters.
Read all positive factors
Philogen SpA (PHIL) vs. iShares MSCI Italy ETF (EWI)
Market Cap
€681.36M
Dividend Yield3.03%
Average Volume (3M)19.28K
Price to Earnings (P/E)4.1
Beta (1Y)-0.13
Revenue Growth324.79%
EPS Growth407.11%
CountryIT
Employees214
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)5.68
Shares Outstanding29,242,860
10 Day Avg. Volume19,753
30 Day Avg. Volume19,281
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.51
Price to Sales (P/S)2.99
P/FCF Ratio3.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.41
Revenue Forecast (FY)€31.65M
Philogen SpA Business Overview & Revenue Model
Company Description
Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic agents for cancer and persistent inflammatory conditions. Among its pipeline, Nidlegy is being developed as an intralesional therapy for localized melanoma and non-melanoma ...
How the Company Makes Money
Philogen’s revenue model is primarily driven by monetizing its drug-development and biologics platform through a mix of (i) collaboration and licensing-related income and (ii) funding tied to development work, alongside (iii) potential future comm...
Philogen SpA Financial Statement Overview
Summary
Income Statement
96
Very Positive
Balance Sheet
94
Very Positive
Cash Flow
95
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 314.32M | 74.00M | 23.13M | 23.71M | 2.50M |
| Gross Profit | 271.84M | 54.42M | 5.67M | 10.53M | -8.14M |
| EBITDA | 255.84M | 44.75M | -2.05M | -1.17M | -12.98M |
| Net Income | 229.68M | 45.29M | -6.16M | -5.38M | -15.72M |
Balance Sheet | |||||
| Total Assets | 437.33M | 168.45M | 119.27M | 125.83M | 132.75M |
| Cash, Cash Equivalents and Short-Term Investments | 379.22M | 113.73M | 75.34M | 86.20M | 101.68M |
| Total Debt | 10.88M | 11.54M | 14.91M | 15.76M | 16.49M |
| Total Liabilities | 63.46M | 29.80M | 28.68M | 27.91M | 27.67M |
| Stockholders Equity | 373.86M | 138.66M | 90.59M | 97.92M | 105.09M |
Cash Flow | |||||
| Free Cash Flow | 268.05M | 38.67M | -10.37M | -9.15M | -25.85M |
| Operating Cash Flow | 271.44M | 40.84M | -4.82M | -4.94M | -19.03M |
| Investing Cash Flow | -171.82M | -22.28M | 159.00K | 24.20M | -47.77M |
| Financing Cash Flow | -2.99M | -3.78M | -4.17M | -3.78M | 63.05M |
Philogen SpA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
86 Outperform | €681.36M | 4.10 | 45.54% | 2.89% | 324.79% | 407.11% | |
79 Outperform | €10.83B | 21.60 | 24.25% | 2.61% | 9.10% | 22.99% | |
77 Outperform | €1.26B | 14.88 | 16.55% | 1.60% | 4.42% | -16.04% | |
73 Outperform | €4.01B | 23.18 | 11.29% | 1.95% | -3.13% | -22.16% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
43 Neutral | €10.25M | -0.30 | 17.04% | ― | 74.59% | ― |
* General Sector Average
IT:PHIL
Philogen SpA
23.30
2.08
9.81%
IT:DIA
DiaSorin S.p.A.
74.42
-8.76
-10.53%
IT:ELN
El.En. S.p.A.
15.62
4.08
35.41%
IT:FDA
Fidia Spa
0.01
-0.27
-96.43%
IT:REC
Recordati Industria Chimica e Farmaceutica SPA
52.50
2.10
4.16%
IT:ARBS
Arterra Bioscience SpA
3.19
0.75
31.01%
Philogen SpA Corporate Events
Mediobanca Reports Purchase of Philogen Shares on Italian Market
Aug 3, 2026
Philogen S.p.A. disclosed a transaction in its listed shares involving Mediobanca S.p.A., a major Italian financial institution acting under an unspecified engagement. The transaction, executed on July 22, 2026, on the EXM market segment, involved...
Philogen Updates Share Buyback as Treasury Stake Nears 0.9% of Capital
Jul 27, 2026
Philogen S.p.A. has provided an update on its share buyback program, reporting the purchase of 230 treasury shares on Euronext Milan between 20 and 24 July 2026 at an average price of €22.80 per share, for a total outlay of €5,244.00. ...
Philogen resubmits strengthened EMA application for melanoma drug Nidlegy
Jul 27, 2026
Philogen has resubmitted an updated marketing authorization application to the European Medicines Agency for Nidlegy as a neoadjuvant therapy in adult patients with locally advanced, fully resectable melanoma. The dossier is now supported by longe...
Philogen Publishes Shareholders’ Meeting Minutes and Highlights Targeted Cancer-Drug Focus
May 21, 2026
Philogen S.p.A., an Italian-Swiss biotechnology group, focuses on developing targeted anticancer therapies that use proprietary ligands, including monoclonal antibodies and small molecules, to deliver powerful agents directly to tumors while limit...
Philogen Maintains Strong Cash Position as Oncology Pipeline Advances on Schedule
May 12, 2026
Philogen reported a solid financial position for the first quarter of 2026, with a positive net financial position of €355.4 million and liquidity of €366.1 million, only slightly lower than year-end despite operating and financial exp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.